Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

Also called NCT03549923

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 131 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03549923
Other papers using this trial's data
  • Effects of early continuous renal replacement therapy in critically ill patients requiring ECMO treatment: results of a randomised controlled trial Open heart, 2026-07-09 DOI, PubMed 42425722, PMC13358276 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03549923. Randomized; no masking; primary purpose treatment. Start 2018-12-18 (actual); primary completion 2022-10-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)
Acronym
ELITE
Condition
Cardiogenic Shock
Intervention (Device)
Simultaneous CRRT
Intervention (Device)
Conventional-indication CRRT
Intervention (Drug)
Esmolol
Intervention (Drug)
Standard care
Lead sponsor
Beijing Anzhen Hospital (class: other)
Collaborator
The First Affiliated Hospital of Zhengzhou University (class: other)

Record details

Record id
cardio:ct-nct03549923
Content hash
7ba34760dd68348f1556e2f4840ae688845cef295867832dad695073e3164b88